A trial looking at taladegib for small cell lung cancer

Cancer type:

Lung cancer

Secondary cancers

Small cell lung cancer

Status:

Results

Phase:

Phase 1/2

This trial looked at taladegib (LY2940680) with carboplatin and etoposide chemotherapy for small cell lung cancer. It was for people whose cancer had spread beyond the lungs.

It was open for people to join between 2013 and 2014. The team analysed the results in 2018. There are links to more information in the ‘Summary of results’ section below.

More about this trial

Small cell lung cancer (SCLC) that has spread within the chest or to another part of the body is called extensive disease. Doctors usually treat extensive disease with chemotherapy. When this trial was done, they often used a combination of carboplatin and etoposide.

Taladegib is a type of targeted cancer treatment called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.

There were two parts to this trial.

In part 1, everyone had carboplatin and etoposide chemotherapy and taladegib capsules. They had various doses of taladegib.

In part 2, people were due to have either:

carboplatin and etoposide with taladegib capsules
carboplatin and etoposide with dummy (placebo) capsules

But the trial was closed earlier than planned, before part 2 started.

The main aims of this trial were to find out:

the best dose of taladegib to give with carboplatin and etoposide
how well taladegib, carboplatin and etoposide works for extensive stage small cell lung cancer
more about the side effects